Literature DB >> 12271415

Persistent non-specific FDG uptake on PET imaging following hip arthroplasty.

Hongming Zhuang1, Thomas K Chacko, Marc Hickeson, Karen Stevenson, Qi Feng, Fabio Ponzo, Jonathan P Garino, Abass Alavi.   

Abstract

Hip arthroplasty is a common surgical procedure, but the diagnosis of infection associated with hip arthroplasty remains challenging. Fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has been shown to be a promising imaging modality in settings where infection is suspected. However, inflammatory reaction to surgery can result in increased FDG uptake at various anatomic locations, which may erroneously be interpreted as sites of infection. The purpose of this study was to assess the patterns and time course of FDG accumulation following total hip replacement over an extended period of time. Firstly, in a prospective study nine patients with total hip replacement were investigated to determine the patterns of FDG uptake over time. Three FDG-PET scans were performed in each patient at about 3, 6 and 12 months post arthroplasty. Secondly, in a retrospective analysis, the medical and surgical history and FDG-PET imaging results of 710 patients who had undergone whole-body scans for the evaluation of possible malignant disorders were reviewed. The history of arthroplasty and FDG-PET findings in the hip region were reviewed for this study. Patients with symptomatic arthroplasties or related complaints during FDG-PET scanning were excluded from the analysis. During the entire study period, all nine patients enrolled in the prospective study were demonstrated to have increased FDG uptake around the femoral head or neck portion of the prosthesis that extended to the soft tissues surrounding the femur. Among the patients reviewed in the retrospective study, 18 patients with a history of 21 hip arthroplasties who were asymptomatic at the time of FDG-PET scan met the criteria for inclusion. The time interval between the hip arthroplasty and the FDG-PET study ranged from 3 months to 288 months (mean+/-SD: 80.4+/-86.2 months). In 81% (17 of 21) of these prostheses, increased FDG uptake could be noted around the femoral head or neck portion of the prosthesis. The average time interval between arthroplasty and FDG-PET scan in these patients was 71.3 months. In only four prostheses (19%, 4 of 21) was no abnormally increased FDG uptake seen around the prostheses or adjacent sites. The average time interval in these patients was 114.8 months. It is concluded that following hip arthroplasty, non-specifically increased FDG uptake around the head or neck of the prosthesis persists for many years, even in patients without any complications. Therefore, to minimize the number of false-positive results for infection with PET studies obtained to evaluate a painful hip prosthesis, caution should be exercised when interpreting FDG uptake around the head or neck portion of the prosthesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271415     DOI: 10.1007/s00259-002-0886-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  28 in total

1.  The value of (18)FDG-PET for the detection of infected hip prosthesis.

Authors:  Benedicte Vanquickenborne; Alex Maes; Johan Nuyts; Frank Van Acker; Jos Stuyck; Michiel Mulier; Alfons Verbruggen; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-04       Impact factor: 9.236

Review 2.  FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis.

Authors:  Thomas C Kwee; Robert M Kwee; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11       Impact factor: 9.236

Review 3.  Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Authors:  Kathleen Carey; Babak Saboury; Sandip Basu; Alex Brothers; Alexis Ogdie; Tom Werner; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-14       Impact factor: 9.236

4.  Should well-fixed uncemented femoral components be revised in infected hip arthroplasty? Report of five trial cases.

Authors:  Kiyokazu Fukui; Ayumi Kaneuji; Syusuke Ueda; Tadami Matsumoto
Journal:  J Orthop       Date:  2015-11-01

Review 5.  Prosthetic joint infections: radionuclide state-of-the-art imaging.

Authors:  Filip Gemmel; Hans Van den Wyngaert; Charito Love; M M Welling; Paul Gemmel; Christopher J Palestro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-24       Impact factor: 9.236

6.  FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-08       Impact factor: 9.236

7.  Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer.

Authors:  Kelly E Henry; Thomas R Dilling; Dalya Abdel-Atti; Kimberly J Edwards; Michael J Evans; Jason S Lewis
Journal:  J Nucl Med       Date:  2017-08-28       Impact factor: 10.057

8.  Role of FDG-PET and PET/CT in the diagnosis of prolonged febrile states.

Authors:  M Jaruskova; O Belohlavek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

Review 9.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection.

Authors:  Sabire Yılmaz Aksoy; Sertac Asa; Meftune Ozhan; Meltem Ocak; M Sait Sager; Melih Engin Erkan; Metin Halac; Levent Kabasakal; Kerim Sönmezoglu; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.